90 results on '"Castella, Barbara"'
Search Results
2. Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models.
3. MM-324 Effects of Soluble and Microvesicle-Bound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
4. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer
5. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells
6. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus Acute Lymphoblastic Leukemia study
7. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside
8. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid
9. Molecular dynamics of targeting CD38 in multiple myeloma.
10. Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia.
11. Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma.
12. Mechanisms of Vgamma9Vdelta2 T cell activation by soluble metabolites generated by the mevalonate pathway
13. Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia
14. The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells
15. IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA
16. Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma
17. Poster: MM-324 Effects of Soluble and Microvesicle-Bound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
18. Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression.
19. ABCA1, apoA-i, and BTn3A1: A Legitimate Ménage à Trois in Dendritic Cells.
20. Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL)
21. SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA
22. Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells
23. SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THEIDENTIFICATION OF NOVEL TUMOR-ASSOCIATED ANTIGENS INCHRONIC LYMPHOCYTIC LEUKEMIA
24. Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia
25. Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells
26. Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross Talk between V{gamma}9V{delta}2 T Cells, {alpha}{beta} CD8+ T Cells, Regulatory T Cells, and Dendritic Cells
27. IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS
28. Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL)
29. Molecular Pathways Responsible for Adaptive Resistance to Single-Checkpoint Inhibition May Reveal Biomarkers and Immunotherapy Targets in Multiple Myeloma Patients
30. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity upon short-term incubation with zoledronic acid
31. Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma
32. CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab.
33. ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID
34. ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and Vγ9Vδ2 T-Cell Activation By Dendritic Cells
35. The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection
36. Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.
37. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
38. Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition.
39. Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells.
40. Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between Vγ9Vδ2 T Cells, αβ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells.
41. The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells
42. Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells.
43. Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?
44. The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells.
45. Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations.
46. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia
47. Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status.
48. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.
49. Metabolic approaches to rescue antitumor Vγ9Vδ2 T-cell functions in myeloma.
50. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.